



Universiteit  
Leiden  
The Netherlands

## **Advances in clinical development for vaccines and therapeutics against respiratory virus infections**

J.L. van der Plas

### **Citation**

*Advances in clinical development for vaccines and therapeutics against respiratory virus infections.* (2023, September 26). *Advances in clinical development for vaccines and therapeutics against respiratory virus infections.* Retrieved from <https://hdl.handle.net/1887/3642223>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3642223>

**Note:** To cite this publication please use the final published version (if applicable).

ADVANCES IN  
CLINICAL DEVELOPMENT  
FOR VACCINES AND  
THERAPEUTICS  
AGAINST RESPIRATORY  
VIRUS INFECTIONS

Proefschrift

ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op dinsdag 26 september 2023

klokke 11.15 uur

door

Johan Leendert van der Plas  
geboren te Katwijk aan Zee

in 1991

© J.L. van der Plas, 2023

DESIGN: Caroline de Lint, Den Haag (caro@delint.nl)

IMAGE: Electron microscopy image framed in blue

Publication of this thesis was financially supported by the foundation  
Centre for Human Drug Research in Leiden, the Netherlands.

**PROMOTOR**

Prof. dr. J. Burggraaf

**CO-PROMOTOR**

Dr. I.M.C. de Visser-Kamerling

**LEDEN PROMOTIECOMMISSIE**

Prof. dr. L.G. Visser

Prof. dr. W.J.M. Spaan

Prof. dr. B.C.P. Koch (*Erasmus Medisch Centrum, Rotterdam*)

Prof. dr. M. van Egmond (*Amsterdam Universitair Medisch Centrum, Amsterdam*)

8	<b>CHAPTER 1</b> Introduction
	<b>SECTION 1 RESPIRATORY SYNCYTIAL VIRUS</b>
24	<b>CHAPTER 2</b> Prevalent levels of rsv serum neutralizing antibodies in healthy adults outside the rsv-season
36	<b>CHAPTER 3</b> First-in-human administration of a live-attenuated rsv vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
	<b>SECTION 2 INFLUENZA VIRUS</b>
60	<b>CHAPTER 4</b> Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM®): a randomized, double-blind, controlled, ascending dose study in healthy adults and elderly
	<b>SECTION 3 SARS-COV-2 AND CLINICAL DEVELOPMENT DURING PANDEMICS</b>
86	<b>CHAPTER 5</b> Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19 – a phase 2a, open-label, single dose escalation study
106	<b>CHAPTER 6</b> Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study
128	<b>CHAPTER 7</b> Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation
146	<b>CHAPTER 8</b> How to expedite early-phase SARS-cov-2 vaccine trials in pandemic setting-A practical perspective
154	<b>CHAPTER 9</b> Discussion and future perspectives
168	Nederlandse samenvatting
181	Curriculum Vitae
182	List of publications